ESR1 and breast carcinoma: Recently, genome-wide transcriptomic analysis in 134 patients with metastatic ERα-positive breast cancer also revealed that AP-2γ levels demonstrated a strong negative correlation with the response to fulvestrant treatment.[30] The evidence together strongly suggests AP-2γ expression levels possess great prognostic value for antihormone treatment.